Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant contributions from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes the company's self-developed BFA01 adjuvant [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix, indicating a competitive landscape for Ruike's new product [3]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued a notice regarding the overseas issuance and listing of Yudi Robotics (Wuxi) Co., Ltd., allowing the company to issue up to 73,600,000 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [1] - A total of 33 shareholders plan to convert their combined 237,232,625 shares of unlisted domestic shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Group 2 - The largest shareholder, Beijing Junlian Chengye Equity Investment Partnership, plans to convert 29,775,900 shares [4] - Other significant shareholders include Lazars Network Technology (Shanghai) Co., Ltd. with 29,342,250 shares and Hainan Yunfeng Fund Center (Limited Partnership) with 23,750,650 shares [4][5] - The total number of shares being converted by the listed shareholders amounts to 237,232,625 shares [5]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a notice regarding the overseas issuance and listing of shares for Youdi Robotics (Wuxi) Co., Ltd., allowing the company to issue up to 73,600,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange [1][3]. Group 1 - The company plans to issue a maximum of 73,600,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange [3][4]. - A total of 33 shareholders intend to convert 237,232,625 shares of unlisted domestic shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1][4]. - The company must report any significant events to the CSRC through the management information system before the completion of the overseas issuance and listing [4]. Group 2 - The company is required to report the status of the overseas issuance and share conversion within 15 working days after the completion of the overseas listing [4]. - If the company does not complete the overseas issuance and share conversion within 12 months from the date of the notice, it must update the filing materials to continue the process [5]. - The notice does not imply any judgment or guarantee regarding the investment value or returns for investors from the CSRC [5].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has approved Beijing Xiantong International Pharmaceutical Technology Co., Ltd. to issue up to 9,259,900 overseas listed ordinary shares and to list on the Hong Kong Stock Exchange, along with the conversion of 34,466,214 domestic unlisted shares into overseas listed shares by 95 shareholders [1]. Company Overview - Xiantong Pharmaceutical is a leader in the Chinese radiopharmaceutical market, focusing on the development and commercialization of innovative radiopharmaceuticals with the potential to be the first listed or best-in-class in China [1]. - The company is recognized as the first in China to obtain marketing approval for innovative radiopharmaceuticals, to receive production licensing as a Marketing Authorization Holder (MAH), and to complete clinical trials for therapeutic radioligands accepted by the National Medical Products Administration (NMPA) [1]. Shareholder Participation - A total of 95 shareholders are involved in the conversion of shares, with significant contributions from various investment funds and individuals, including: - Xu Xingsheng: 3,343,071 shares - Jiangsu Jiequan Chengda Equity Investment Center: 2,959,381 shares - Jinshi Manufacturing Transformation and Upgrading New Materials Fund: 2,276,447 shares - China State-Owned Enterprises Structural Adjustment Fund II: 1,707,335 shares [1][2].

Core Points - The China Securities Regulatory Commission (CSRC) has issued a notice regarding the "full circulation" registration of unlisted shares for Baiwang Co., Ltd. [1] - A total of 52 shareholders of Baiwang Co., Ltd. plan to convert 135,064,706 shares from unlisted to listed shares for trading on the Hong Kong Stock Exchange [1] - If the share conversion is not completed within 12 months from the issuance of the notice, the company must update its registration materials to continue the process [1] Financial Performance - Baiwang Co., Ltd. reported a revenue of 348 million yuan for the six months ending June 30, 2025, representing a year-on-year increase of 23.45% [4] - The gross profit for the same period was 162 million yuan, showing a year-on-year increase of 46.84% [4] - The company achieved a net profit attributable to shareholders of 3.717 million yuan, a turnaround from a loss of 44.6 million yuan in the same period last year, resulting in a basic earnings per share of 0.02 yuan [4]

Core Viewpoint - The Hong Kong stock market experienced a decline across all major indices, while AI solution provider Yunzhisheng (9678.HK) saw a significant increase of 26.55% to HKD 591 due to its announcement regarding the conversion of non-listed shares to H-shares [1] Company Summary - Yunzhisheng announced that it has submitted an application to the China Securities Regulatory Commission (CSRC) to convert 24,488,277 domestic non-listed shares and 4,570,649 non-listed foreign shares into H-shares [1] - The conversion will allow these shares to be listed and traded on the main board of the Hong Kong Stock Exchange, pending approval from relevant regulatory bodies including the CSRC and the Stock Exchange [1] - As of the announcement date, the company has not yet completed the filing with the CSRC regarding this application and will provide further updates on the progress and details at an appropriate time [1]

Core Viewpoint - The company Yunzhisheng (09678) has submitted an application to the China Securities Regulatory Commission (CSRC) to convert a total of 24.4883 million domestic unlisted shares and 4.5706 million unlisted foreign shares into H-shares for listing on the Hong Kong Stock Exchange [1] Group 1 - The total number of domestic unlisted shares to be converted is 24.4883 million [1] - The total number of unlisted foreign shares to be converted is 4.5706 million [1] - The conversion is subject to approval from relevant regulatory bodies, including the CSRC and the Hong Kong Stock Exchange [1]

Group 1 - The China Securities Regulatory Commission has issued a notification regarding the "full circulation" of unlisted shares for Guohong Hydrogen Energy Technology (Jiaxing) Co., Ltd, allowing 12 shareholders to convert a total of 41,303,978 shares into listed shares on the Hong Kong Stock Exchange [1] - The company must complete the share conversion within 12 months from the date of the notification, or it will need to update its filing materials if it wishes to continue the process [1] Group 2 - According to Frost & Sullivan, the company is a leading player in China's hydrogen fuel cell industry, ranking first in hydrogen fuel cell stack shipments from 2017 to 2022 [4] - The company ranked first in sales value of hydrogen fuel cell systems in 2022 and second in sales volume of hydrogen fuel cell systems in the same year [4]

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission (CSRC) to convert 9,286,359 domestic shares into H-shares, pending regulatory approvals [1] Group 1 - The conversion of shares is aimed at allowing the unlisted shares to be traded on the main board of the Stock Exchange of Hong Kong [1] - The company has not yet completed the filing with the CSRC as of the date of the announcement [1]